Clinical trials: Streptococcus Infection
Group B Streptococcus Infection
A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers
The goal of this follow-up study is to investigate the persistence of the immune response induced by the GBS-NN/NN2 vaccine in women who have participated in study MVX0002, and/or in study MVX0003 with GBS-NN/NN2 vaccine and…
- Trial name
- NCT06280157
- Testing
- GBS-NN/NN2
- Where
- United Kingdom
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Minervax ApS
Group B Streptococcal Infection
Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial
Group B Streptococcus (GBS) is the leading cause of neonatal morbidity and mortality in Canada. It may be passed from a study participant colonized in the genital tract by GBS to their baby during vaginal birth.
- Trial name
- NCT02528981
- Testing
- Probiotic
- Where
- Canada
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Toronto Metropolitan University
Streptococcus Group A
Prevalence of RHD, Pyoderma and Scabies in Children in Fiji
The purpose of this study is to estimate the number of cases of rheumatic heart disease, pyoderma, and scabies in school age children in Fiji.
- Trial name
- NCT00284843
- Where
- Fiji
- Volunteers
- 5,200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumococcal Infectious Disease
A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
A phase 1b clinical trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 months (42-89 days) and 2 to 5 years.
- Trial name
- NCT06183216
- Testing
- Sinovac PCV13, PREVNAR 13
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Pneumococcal Infection
A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants
The purpose of this study is to evaluate the safety and immunogenicity of LBVE (Multivalent Pneumococcal Conjugate Vaccine) in healthy infants.
- Trial name
- NCT03467984
- Testing
- LBVE, Prevnar13
- Where
- South Korea
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- LG Chem
Infections, Streptococcal, Streptococcus Pneumoniae
Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™
The aim of this study is to assess the immune response, safety and reactogenicity following administration of an additional dose of a pneumococcal conjugate vaccine at approximately 4 years of age in children previously…
- Trial name
- NCT00907777
- Testing
- Pneumococcal conjugate vaccine GSK 1024850A, Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)
- Where
- 17 sites in Germany
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatic Heart Disease, Rheumatic Heart Disease in Children
Clinical Trial Phase I/IIa to Evaluate the Safety and Immunogenicity of StreptInCor
This is a Phase I/IIa, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to test the candidate vaccine StreptInCor.
- Conditions
- Rheumatic Heart Disease, Rheumatic Heart Disease in Children, Vaccine Adverse Reaction, Rheumatic Diseases
- Trial name
- StreptInCorVac (NCT07078357)
- Testing
- StrepIncor
- Where
- Brazil
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Pneumococcal Infectious Disease
Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years
Phase I clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in children aged 2 Months (Minimum 6 Weeks) to 17 Years .
- Trial name
- NCT06675032
- Testing
- PCV24 formulation 1, PCV24 formulation 2, 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
- Where
- China
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Reinovax Biologics Co., LTD
Pneumococcal Infections
Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.
This is a randomised placebo-controlled first-in-man dose-ranging study to determine safety and markers of efficacy.
- Trial name
- NCT05667740
- Testing
- Gamma-PN3, Prevenar-13, Pneumovax-23
- Where
- Australia
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- GPN Vaccines
Pneumococcal Infections
Long-term Impact of Pneumococcal Conjugate Vaccine on Carriage
Pneumococcus is a major cause of morbidity and mortality. In 2000, a pneumococcal conjugate vaccine (PCV) was licensed for use in children and is now part of the routine childhood vaccine schedule.
- Trial name
- NCT00294021
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Pneumococcal Pneumonia
PCV10 Reactogenicity and Immunogenicity Study - Malindi
The World Health Organization has recommended that developing countries should incorporate pneumococcal conjugate vaccine (PCV) into their routine immunization schedules.
- Trial name
- PRISM (NCT01028326)
- Testing
- PCV10 and DTaP, hepatitis A vaccine, DTaP, PCV10
- Where
- Kenya
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- KEMRI-Wellcome Trust Collaborative Research Program
Interstitial Lung Disease, Systemic Autoimmune Disease
ILD-SARDs Registry and Biorepository
A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways.
- Conditions
- Interstitial Lung Disease, Systemic Autoimmune Disease, Rheumatic Diseases, Rheumatic Arthritis
- Trial name
- ILD-SARDs (NCT05007340)
- Testing
- Blood draws, Other biological samples to biobank (skin, lung and muscle biopsies; bronchoalveolar lavage (BAL fluid), Clinical data collection
- Where
- Canada
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Group B Strep Infection
Group B Streptococcus Vaccine in Healthy Females
A Phase I, randomised, single centre, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and immunogenicity of two doses of Group B Streptococcus vaccine.
- Trial name
- MVX0002 (NCT03807245)
- Testing
- GBS-NN/NN2 with Alhydrogel® 25, GBS-NN/NN2 with Alhydrogel® 50
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Minervax ApS
Rheumatic Heart Disease in Children
School-based Program for the Prevention of Rheumatic Heart Disease in Endemic Regions
The overall objective of the PREVENT trial is to evaluate the effectiveness of an integrated, school-based program for the prevention of rheumatic heart disease (RHD) in regions with an endemic pattern of RHD.
- Trial name
- PREVENT (NCT06720272)
- Testing
- School nurse program
- Where
- 2 sites in Nepal, Zambia
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Thomas Pilgrim
Pneumococcal Infections
Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar®
Primary Objective: To evaluate the impact of PCV7 vaccination on NP carriage rate of vaccine serotypes and serotype distribution Secondary Objective: To evaluate the impact of PCV7 vaccination on NP carriage of antibiotic…
- Trial name
- NCT00488371
- Testing
- Pneumococcal Conjugated Vaccine (Prevnar®)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections
Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS
This study is an investigation of the neurologic, immunologic, and rheumatologic markers of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS).
- Conditions
- Pediatric Acute-Onset Neuropsychiatric Syndrome, Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections, PANS, PANDAS
- Trial name
- NCT02889016
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Stanford University
Pneumococcal Disease
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
The purpose of the study is to describe the safety and immunogenicity of Pneumococcal Conjugate Formulations in healthy adults 18 through 49 years of age.
- Trial name
- NCT05489328
- Testing
- Candidate-1, Candidate-2, Candidate-3
- Where
- 18 sites in United States
- Volunteers
- 394 people, healthy volunteers welcome
- Sponsor
- Pfizer
Infections, Streptococcal
Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine
The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of a booster (fourth) dose of pneumococcal vaccine GSK1024850A when co-administered with Hiberix at 12-18 months of age, in children primed…
- Trial name
- NCT00911144
- Testing
- GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A), Wyeth-Lederle's Prevenar™, GSK Biologicals' Hiberix™
- Where
- 14 sites in South Korea
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Periodontal Diseases, Dental Plaque
Oral Health Literacy Tailored Communication
The purpose of this study to investigate attitude, oral health literacy and psychological factors in order to evaluate if these factors are important for oral health in adults.
- Conditions
- Periodontal Diseases, Dental Plaque, Dental Calculus, Sialorrhea
- Trial name
- NCT01118143
- Testing
- Tailored oral health literacy instruction
- Where
- 2 sites in Norway
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- University of Tromso
Pneumonia
Etiology and Incidence Assessment of Radiographically-confirmed Community Acquired Pneumonia (CAP)
This is an epidemiological study to investigate the etiology of radiographically-confirmed community-acquired pneumonia (CAP) in adults aged ≥18 years.
- Trial name
- OSPIS (NCT03606135)
- Testing
- The Pneumonia Group, The Control Group
- Where
- Sweden
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Region Skane